Black Diamond Therapeutics Inc
BDTX2.255USD
+0.095+4.40%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
128.41MMarktkapitalisierung
5.95KGV TTM
mehr Informationen über Black Diamond Therapeutics Inc Unternehmen
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Inc Informationen
BörsenkürzelBDTX
Name des UnternehmensBlack Diamond Therapeutics Inc
IPO-datumJan 30, 2020
CEOVelleca (Mark A)
Anzahl der mitarbeiter24
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
Addresse245 First Street, 18Th Floor
StadtCAMBRIDGE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02142
Telefon16174175868
Websitehttps://www.blackdiamondtherapeutics.com/
BörsenkürzelBDTX
IPO-datumJan 30, 2020
CEOVelleca (Mark A)
Führungskräfte von Black Diamond Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
86.65K
+5208.00%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
+85150.00%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-20.00%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
31.03K
+4665.00%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
86.65K
+5208.00%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
+85150.00%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-20.00%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
31.03K
+4665.00%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Andere
48.86%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Andere
48.86%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
30.63%
Investment Advisor/Hedge Fund
20.77%
Venture Capital
19.08%
Hedge Fund
7.72%
Research Firm
1.42%
Individual Investor
0.92%
Pension Fund
0.02%
Andere
19.44%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
251
45.27M
104.04%
+4.70K
2025Q3
261
45.26M
106.75%
+270.69K
2025Q2
263
45.72M
119.11%
-2.33M
2025Q1
244
48.05M
134.35%
-28.07M
2024Q4
236
55.25M
127.86%
-855.91K
2024Q3
237
56.09M
121.86%
+1.99M
2024Q2
230
54.06M
101.77%
+8.09M
2024Q1
233
46.69M
117.14%
-13.89M
2023Q4
222
46.16M
104.70%
+1.30M
2023Q3
240
44.37M
104.97%
-4.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Investment Management, Inc.
10.74M
18.86%
+231.97K
+2.21%
Sep 30, 2025
Versant Ventures
6.21M
10.89%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.55M
9.74%
-50.00K
-0.89%
Sep 30, 2025
New Enterprise Associates (NEA)
4.45M
7.81%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.19M
3.84%
+85.83K
+4.08%
Sep 30, 2025
Tang Capital Management, LLC
2.07M
3.63%
--
--
Sep 30, 2025
Marshall Wace LLP
1.30M
2.28%
+561.33K
+76.07%
Sep 30, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
896.85K
1.57%
+758.71K
+549.22%
Sep 30, 2025
Millennium Management LLC
850.33K
1.49%
-94.52K
-10.00%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Fidelity Enhanced Small Cap ETF
0.05%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
DFA Dimensional US Small Cap Value ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Health Innovation Active ETF
0%
Vanguard US Momentum Factor ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Mehr Anzeigen
Fidelity Enhanced Small Cap ETF
Anteil0.05%
iShares Micro-Cap ETF
Anteil0.03%
Avantis US Small Cap Equity ETF
Anteil0.02%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
DFA Dimensional US Small Cap Value ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
iShares Health Innovation Active ETF
Anteil0%
Vanguard US Momentum Factor ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
